Neoral conversion in stable thoracic transplant patients leads to dose reduction

Transplantation Proceedings

Volumn 30, Issue 5, 1998, Pages 1898-1899

  Zaldonis, D B ^a   Keenan, R J ^a   Pham, S M ^a   Kormos, R L ^a   Griffith, B P ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG FORMULATION; ECONOMIC ASPECT; FEMALE; HEART LUNG TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; CREATININE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 0031706577     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(98)00474-6     Document Type: Conference Paper

References (6)

1. Grevel J: Transplant Proc 18(supp5):9, 1986
2. Drewe J, Beglinger C, Kissel T: Br J Clin Pharmcol 33:39, 1992
3. Kovarik JM, Pharm D, Mueller EA: Pharmacotherapy 13:613, 1993
4. Trull AK, Tan KKC, Uttridge J: Lancet 341:433, 1993
5. Mueller EA, Kovarik JM, Van Bree JB, et al: Transplantation 57:1178, 1994
6. Farber L, Maibucher A, Geissler F, et al: Transplantation Proc 26:2988, 1994